A small molecule inhibitor of PAI-1 protects against Doxorubicin-induced cellular senescence

molecular basis

Asish K Ghosh, Rahul Rai, Kitae E. Park, Mesut Eren, Toshio Miyata, Lisa D Wilsbacher, Douglas E Vaughan*

*Corresponding author for this work

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Doxorubicin, an anthracycline antibiotic, is a commonly used anticancer drug. In spite of its widespread usage, its therapeutic effect is limited by its cardiotoxicity. On the cellular level, Doxorubicin-induced cardiotoxicity manifests as stress induced premature senescence. Previously, we demonstrated that plasminogen activator inhibitor-1 (PAI-1), a potent inhibitor of serine proteases, is an important biomarker and regulator of cellular senescence and aging. Here, we tested the hypothesis that pharmacological inhibition of cellular PAI-1 protects against stress- and aging-induced cellular senescence and delineated the molecular basis of protective action of PAI- 1 inhibition. Results show that TM5441, a potent small molecule inhibitor of PAI-1, effectively prevents Doxorubicin-induced senescence in cardiomyocytes, fibroblasts and endothelial cells. TM5441 exerts its inhibitory effect on Doxorubicin-induced cellular senescence by decreasing reactive oxygen species generation, induction of antioxidants like catalase and suppression of stress-induced senescence cadre p53, p21, p16, PAI-1 and IGFBP3. Importantly, TM5441 also reduces replicative senescence of fibroblasts. Together these results for the first time demonstrate the efficacy of PAI-1 inhibitor in prevention of Doxorubicin-induced and replicative senescence in normal cells. Thus PAI-1 inhibitor may form an important adjuvant component of chemotherapy regimens, limiting not only Doxorubicin-induced cardiac senescence but also ameliorating the prothrombotic profile.

Original languageEnglish (US)
Pages (from-to)72443-72457
Number of pages15
JournalOncotarget
Volume7
Issue number45
DOIs
StatePublished - Oct 6 2016

Fingerprint

Cell Aging
Plasminogen Activator Inhibitor 1
Doxorubicin
Fibroblasts
Serine Proteinase Inhibitors
Anthracyclines
Therapeutic Uses
Adjuvant Chemotherapy
Cardiac Myocytes
Catalase
Reactive Oxygen Species
Endothelial Cells
Antioxidants
Biomarkers
Pharmacology
Anti-Bacterial Agents
Pharmaceutical Preparations

Keywords

  • Cardiomyocytes
  • Cellular senescence
  • Doxorubicin
  • Endothelial cells
  • Fibroblasts

ASJC Scopus subject areas

  • Oncology

Cite this

@article{605551abb2e14f729864514f5263594e,
title = "A small molecule inhibitor of PAI-1 protects against Doxorubicin-induced cellular senescence: molecular basis",
abstract = "Doxorubicin, an anthracycline antibiotic, is a commonly used anticancer drug. In spite of its widespread usage, its therapeutic effect is limited by its cardiotoxicity. On the cellular level, Doxorubicin-induced cardiotoxicity manifests as stress induced premature senescence. Previously, we demonstrated that plasminogen activator inhibitor-1 (PAI-1), a potent inhibitor of serine proteases, is an important biomarker and regulator of cellular senescence and aging. Here, we tested the hypothesis that pharmacological inhibition of cellular PAI-1 protects against stress- and aging-induced cellular senescence and delineated the molecular basis of protective action of PAI- 1 inhibition. Results show that TM5441, a potent small molecule inhibitor of PAI-1, effectively prevents Doxorubicin-induced senescence in cardiomyocytes, fibroblasts and endothelial cells. TM5441 exerts its inhibitory effect on Doxorubicin-induced cellular senescence by decreasing reactive oxygen species generation, induction of antioxidants like catalase and suppression of stress-induced senescence cadre p53, p21, p16, PAI-1 and IGFBP3. Importantly, TM5441 also reduces replicative senescence of fibroblasts. Together these results for the first time demonstrate the efficacy of PAI-1 inhibitor in prevention of Doxorubicin-induced and replicative senescence in normal cells. Thus PAI-1 inhibitor may form an important adjuvant component of chemotherapy regimens, limiting not only Doxorubicin-induced cardiac senescence but also ameliorating the prothrombotic profile.",
keywords = "Cardiomyocytes, Cellular senescence, Doxorubicin, Endothelial cells, Fibroblasts",
author = "Ghosh, {Asish K} and Rahul Rai and Park, {Kitae E.} and Mesut Eren and Toshio Miyata and Wilsbacher, {Lisa D} and Vaughan, {Douglas E}",
year = "2016",
month = "10",
day = "6",
doi = "10.18632/oncotarget.12494",
language = "English (US)",
volume = "7",
pages = "72443--72457",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "45",

}

A small molecule inhibitor of PAI-1 protects against Doxorubicin-induced cellular senescence : molecular basis. / Ghosh, Asish K; Rai, Rahul; Park, Kitae E.; Eren, Mesut; Miyata, Toshio; Wilsbacher, Lisa D; Vaughan, Douglas E.

In: Oncotarget, Vol. 7, No. 45, 06.10.2016, p. 72443-72457.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A small molecule inhibitor of PAI-1 protects against Doxorubicin-induced cellular senescence

T2 - molecular basis

AU - Ghosh, Asish K

AU - Rai, Rahul

AU - Park, Kitae E.

AU - Eren, Mesut

AU - Miyata, Toshio

AU - Wilsbacher, Lisa D

AU - Vaughan, Douglas E

PY - 2016/10/6

Y1 - 2016/10/6

N2 - Doxorubicin, an anthracycline antibiotic, is a commonly used anticancer drug. In spite of its widespread usage, its therapeutic effect is limited by its cardiotoxicity. On the cellular level, Doxorubicin-induced cardiotoxicity manifests as stress induced premature senescence. Previously, we demonstrated that plasminogen activator inhibitor-1 (PAI-1), a potent inhibitor of serine proteases, is an important biomarker and regulator of cellular senescence and aging. Here, we tested the hypothesis that pharmacological inhibition of cellular PAI-1 protects against stress- and aging-induced cellular senescence and delineated the molecular basis of protective action of PAI- 1 inhibition. Results show that TM5441, a potent small molecule inhibitor of PAI-1, effectively prevents Doxorubicin-induced senescence in cardiomyocytes, fibroblasts and endothelial cells. TM5441 exerts its inhibitory effect on Doxorubicin-induced cellular senescence by decreasing reactive oxygen species generation, induction of antioxidants like catalase and suppression of stress-induced senescence cadre p53, p21, p16, PAI-1 and IGFBP3. Importantly, TM5441 also reduces replicative senescence of fibroblasts. Together these results for the first time demonstrate the efficacy of PAI-1 inhibitor in prevention of Doxorubicin-induced and replicative senescence in normal cells. Thus PAI-1 inhibitor may form an important adjuvant component of chemotherapy regimens, limiting not only Doxorubicin-induced cardiac senescence but also ameliorating the prothrombotic profile.

AB - Doxorubicin, an anthracycline antibiotic, is a commonly used anticancer drug. In spite of its widespread usage, its therapeutic effect is limited by its cardiotoxicity. On the cellular level, Doxorubicin-induced cardiotoxicity manifests as stress induced premature senescence. Previously, we demonstrated that plasminogen activator inhibitor-1 (PAI-1), a potent inhibitor of serine proteases, is an important biomarker and regulator of cellular senescence and aging. Here, we tested the hypothesis that pharmacological inhibition of cellular PAI-1 protects against stress- and aging-induced cellular senescence and delineated the molecular basis of protective action of PAI- 1 inhibition. Results show that TM5441, a potent small molecule inhibitor of PAI-1, effectively prevents Doxorubicin-induced senescence in cardiomyocytes, fibroblasts and endothelial cells. TM5441 exerts its inhibitory effect on Doxorubicin-induced cellular senescence by decreasing reactive oxygen species generation, induction of antioxidants like catalase and suppression of stress-induced senescence cadre p53, p21, p16, PAI-1 and IGFBP3. Importantly, TM5441 also reduces replicative senescence of fibroblasts. Together these results for the first time demonstrate the efficacy of PAI-1 inhibitor in prevention of Doxorubicin-induced and replicative senescence in normal cells. Thus PAI-1 inhibitor may form an important adjuvant component of chemotherapy regimens, limiting not only Doxorubicin-induced cardiac senescence but also ameliorating the prothrombotic profile.

KW - Cardiomyocytes

KW - Cellular senescence

KW - Doxorubicin

KW - Endothelial cells

KW - Fibroblasts

UR - http://www.scopus.com/inward/record.url?scp=84995745327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995745327&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.12494

DO - 10.18632/oncotarget.12494

M3 - Article

VL - 7

SP - 72443

EP - 72457

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 45

ER -